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Abstract 
 
Purpose: The phosphoinositide 3-kinase (PI3K) pathway is fundamental for cell proliferation and 
survival and is frequently altered and activated in neoplasia, including carcinomas of the lung. In 
this study, we investigated the potential of targeting the catalytic class IA PI3K isoforms in small 
cell lung cancer (SCLC), which is the most aggressive of all lung cancer types. 
Experimental Design: The expression of PI3K isoforms in patient specimens was analyzed. 
The effects on SCLC cell survival and downstream signaling were determined following PI3K 
isoform inhibition by selective inhibitors or down-regulation by small interfering RNA. 
Results: Over-expression of the PI3K isoforms p110α and p110β and the anti-apoptotic protein 
Bcl-2 was shown by immunohistochemistry in primary SCLC tissue samples. Targeting the PI3K 
p110α with RNA interference (RNAi) or selective pharmacological inhibitors resulted in strongly 
affected cell proliferation of SCLC cells in vitro and in vivo, while targeting p110β was less 
effective. Inhibition of p110α also resulted in increased apoptosis and autophagy, which was 
accompanied by decreased phosphorylation of Akt and components of the mammalian target of 
rapamycin (mTOR) pathway, such as the ribosomal S6 protein, and the eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1). A DNA microarray analysis revealed that p110α 
inhibition profoundly affected the balance of pro- and anti-apoptotic Bcl-2 family proteins. Finally, 
p110α inhibition led to impaired SCLC tumor formation and vascularization in vivo.  
Conclusion: Together our data demonstrate the key involvement of the PI3K isoform p110α in 
the regulation of multiple tumor-promoting processes in SCLC. 
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Translational relevance 
 
Small cell lung cancer (SCLC) is a common form of lung cancer and is associated with very 
unsatisfactory survival rates. Novel therapies are thus urgently required and will arise from a 
better understanding of the disease biology. We were interested in gaining further insight into the 
potential of targeting PI3K isoforms in SCLC. In this report, we show that the catalytic p110α 
isoform is over-expressed in a subset of primary SCLC samples. The growth of SCLC cells was 
impaired on targeting p110α using RNA interference or specific pharmacologic inhibitors. 
Inhibition of p110α also induced apoptosis and autophagy, which was paralleled by a decrease 
in the expression levels of anti-apoptotic Bcl-2 family proteins. Importantly, SCLC tumors treated 
with p110α inhibitors displayed reduced proliferation and enhanced apoptosis in vivo. Together, 
the results presented in this study show that specific p110α inhibitors may in the future represent 
new drugs for SCLC. 
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Introduction 
 
Lung cancer is a major cause of death in the developed world and the commonest cancer killer 
in men. Small cell lung cancer (SCLC) represents about 13-15% of all cases of lung cancer and 
is strongly associated with cigarette smoking. Combinatorial chemotherapy regimens with 
etoposide and platinum-based agents, as well as radiotherapy, are commonly used for the 
treatment of SCLC patients. However, an initial therapeutic response is usually followed by 
disease recurrence within less than 1 year and therefore the overall 5-year survival rate is <5%. 
Consequently, novel therapeutic strategies are urgently required for SCLC. In the past years, an 
increasing number of molecular alterations involved in SCLC pathogenesis have been reported, 
including ectopic expression of neuroendocrine regulatory peptides, up-regulation of anti-
apoptotic Bcl-2 proteins, overexpression of myc family oncogenes and extracellular matrix 
proteins, as well as genetic abnormalities in the tumor suppressor genes TP53 and RB (1, 2). In 
addition, it has been shown that polypeptide growth factors such as hepatocyte growth factor 
(HGF),  fibroblast growth factor-2 (FGF-2), insulin-like growth factor-1 (IGF-1) and stem cell 
factor (SCF) control key biological responses in human SCLC cells, including growth and 
proliferation, chemoresistance, and migration (3-6). Downstream of activated polypeptide growth 
factor receptors, activation of two major intracellular signaling cascades, the phosphoinositide-3 
kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the mitogen-activated Erk kinase 
(MEK)/extracellular signal-regulated kinase (Erk) pathway, have been found to be involved in the 
survival and proliferation of SCLC (3, 5-8). Furthermore, it has been reported that mTOR and the 
ribosomal protein S6 kinases (S6K) are over-expressed in SCLC cells, compared with normal 
human type II pneumocytes (6). Therefore, targeting these pathways with novel selective 
pharmacological inhibitors may lead to the development of more effective therapies for SCLC. 
The PI3K signaling pathway controls key cellular responses, such as cell growth and 
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proliferation, survival, migration and metabolism. Over the last decades, it has been recognized 
that this intracellular signaling pathway is frequently activated by genetic and epigenetic 
alterations in human cancer, including lung cancer. The PI3K family of signaling enzymes 
comprises eight catalytic isoforms, which are subdivided into three classes. The class IA PI3K 
isoform p110α is considered to be a validated drug target in human cancer (9-11), in particular 
because activating mutations in the PIK3CA frequently occur in human cancer.  In SCLC, 
amplification and mutations of the PIK3CA gene were identified and the p110α and p110β 
isoforms were found over-expressed in cell lines, in addition to deregulation of the 
PI3K/Akt/mTOR pathway (12).  
Here we report for the first time that targeting the class IA PI3K isoform p110α blocks 
SCLC cell growth and survival in vitro and in vivo and present evidence that this isoform plays a 
crucial role in Akt/mTOR pathway activation and Bcl-2 family protein expression. 
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Materials and methods 
 
Antibodies and reagents 
Antibodies: Caspase-3, poly-(ADP-ribose)-polymerase (PARP), Akt, PI3K p110β (Santa Cruz 
Biotechnology), p-AktSer473, p-Bcl2Ser70, Bcl2, Bcl-XL, Bax, Bad, p-4EBP1Thr37/46, p-S6Ser235/236 or p-
S6Ser240/244, S6 protein, PI3K p110α (Cell Signaling Technology), β-actin (Sigma Aldrich), Mcl-1, 
NF-κB (Epitomics). Etoposide, chloroquine, z-VAD-FMK, IKK inhibitor/wedelolactone 
(Calbiochem). RAD001 was supplied by the Novartis Institutes for BioMedical Research Basel, 
Oncology, Switzerland. The PI3K inhibitors PIK75, YM024, TGX221 and PI103 were the kind gift 
of Prof. Shaun Jackson. 
 
Cell lines, cell culture, and cell proliferation 
SCLC cell lines were obtained from the American Type Culture Collection (Suppl. Table 2). The 
human SCLC cell lines H69, H209, H510, and SW2 were cultured in RPMI medium containing 
10% heat-inactivated FCS. Cell viability was analyzed by using MTS [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay, Promega). 
 
Reverse transcription-PCR and TaqMan analysis 
Total cellular RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the 
manufacturer’s instruction. For each reverse transcription-PCR, 1 µg of total RNA was used with 
the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The reaction 
conditions were used according to the manufacturer’s protocol. TaqMan Gene Expression 
Assays for the PI3Ks p110α and p110β, as well as for VEGFA were done according to the 
manufacturer’s instructions (Applied Biosystems). As internal control the expression of GAPDH 
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was analyzed in each sample, separately.  
 
Immunohistochemistry 
Immunoreactivity was evaluated on commercial TMA sections of SCLC (Biomax LC10010 (2 
cores; Female 9 (22.5%), Female age 32-66 yo (mean value 52.5); Male 31 (77.5%), Male age 
34-76 yo (mean value 53.0); Stage I 11, Stage II 20, Stage IIIa 7, Stage IIIb 2; Node negative 12, 
Node positive 28 (22 N1 and 6 N2)) using the PI3K p110α (Cell Signaling Technology, 4249), 
p110β (Abcam, ab55593) and Bcl-2 (Cell Signaling) antibodies in a modification of the antigen 
retrieval technique (13). The antibodies were used at a 1:200 dilution for 1 h at room 
temperature and then processed with Polymer-HRP Kit (BioGenex, San Ramon CA) with 
diaminobenzidine development and Mayer Haematoxylin counterstaining. Breast cancer tissue 
was used as positive external control. Negative controls were obtained by omitting the primary 
antibody. A semi quantitative immunohistochemical score (IHS) was used, including assessment 
of both the percentage of positive cells and the intensity of staining. For the intensity, a score of 
0 to 3, corresponding to negative, weak, moderate and strong positivity, was recorded. The 
range of possible scores was thus 0 to 300. IHS and similar semi-quantitative scoring systems 
have been successfully used for TMA evaluation. Each core was scored individually. One 
observer scored all cases, which were rechecked randomly by the same investigator after a 
period of time. 
Serial sections of paraffin-embedded CAM tumors were de-waxed in xylol and 
rehydrated through graded dilutions of ethanol. Antigen recovery was performed with citrate 
buffer (10mM) in a microwave (800 watts) for 7 min. Endogenous peroxidase activity was 
blocked with 3% H2O2. Sections were incubated in a humid chamber at 4 °C overnight with or 
without (negative controls) active caspase-3 (Abcam, ab2302; recognizes the cleaved active p17 
fragment) and Ki67 (Novus Biologicals, NB110-57147) antibodies. Biotin-conjugated goat anti-
Rabbit (Dako, E0432) and avidin-biotin-horseradish peroxidase complex (Vector Laboratories, 
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Vectastain ABC Kit, PK6100) were used. Bound peroxidase was detected with 3, 3'-
diaminobenzidine substrate. Sections were subsequently counterstained with Hematoxylin and 
mounted in Aquatex (Merck).  
 
Transient transfection and stable transduction of SCLC cells 
SCLC cells were transiently transfected with either non-targeting small interfering RNA (siRNA) 
or SMARTpool siRNA duplexes targeting the PI3K p110α or PI3K p110β, using the Amaxa 
Nucleofector system (Amaxa Biosystems), according to the manufacturer’s protocol. Briefly, 1.5 
x 106 SCLC cells grown in RPMI/10% FCS were transfected with 6 µL of 20 µmol/L siRNA in 100 
µL of Nucleofector Solution V using the program T-16 on the Amaxa Nucleofector. Following 
transfection, cells were transferred into RPMI/10 % FCS overnight, before they were used for 
experiments. 
Lentiviral vectors expressing small hairpin (sh)RNA constructs specifically targeting the 
PI3K p110α (Sigma-Aldrich) were tested for stable knockdown efficiency. The constructs 
shPI3KC_2892 and shPI3KC_3433 were chosen for further experiments since they most 
efficiently silenced p110α. The non-targeting vector SHC002 was used as a control. Lentivirus 
production and transduction of cells was done as described before (14). The vectors contain a 
puromycin resistance gene and stably transduced cell populations were selected for two weeks 
using puromycin at the concentration 1.5 μg/ml. 
 
In vivo experiments 
The effect of the PI3K inhibitor PIK75 on the growth and SCLC tumor formation in vivo were 
assessed on the chorioallantoic membrane (CAM) of chick embryos (15). Briefly, 3 x 106 H69 
SCLC cells were placed in RPMI containing 50% BD Matrigel Matrix (BD Biosciences) on the 
CAM on embryonic day 9. Increasing concentrations of the p110α inhibitors PIK75 were 
deposited with the SCLC cells. Controls were treated with the solvent of the corresponding drug. 
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CAMs were examined for vessel formation under a stereomicroscope. Tumor size and density of 
vessels per area around the tumor were determined using the software Vessel_tracer(16). The 
application of Matrigel without/with PIK75 on the CAM was used as a negative control (Suppl. 
Fig. 3).  
SDS-PAGE and Western blotting 
The assays were done as described before (3). 
 
DNA microarray 
The cDNA microarray analysis was performed at the Functional Genomic Center of the 
University of Zurich. Gene expression data were obtained by hybridizing Human Genome U133 
Plus 2.0 Affymetrix Gene Chips arrays, on which >54000 transcripts were represented. Each 
experiment represented a group of three independent biological replicates. Raw data generated 
by the GCOS Software (Affymetrix) were processed by using the RMA method (17) and further 
statistically analyzed by using the software R and applying Student’s t-test. The GeneGO 
MetaCore (GeneGO, St Joseph, MI, USA) was used to define functional annotations for the 
selected genes, thus assigning them to ontological categories for association with relevant 
biological processes and pathways. The accession number of the data in Gene Expression 
Omnibus is GSE40564. 
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Results 
 
Expression of the PI3K p110α and p110β and the anti-apoptotic protein Bcl-2 in SCLC 
patient samples 
Our previous work in SCLC cell lines had revealed that class IA PI3K isoforms are over-
expressed in comparison to type II pneumocytes, which are one of the precursors of SCLC. To 
investigate whether this finding could be confirmed in primary tumors, a SCLC tissue microarray 
was stained with antibodies specific for p110α or p110β (Fig. 1A). This analysis revealed that, 
while normal lung tissue did not express detectable levels of either PI3K isoforms, p110α and 
p110β displayed enhanced expression in subsets of primary SCLC (Fig. 1A-B). Around 25% of 
SCLC tumors showed over-expression of p110α, while 18% of cases were positive for p110β 
(Fig. 1B). In general, SCLC tumors did not display concomitant over-expression of p110α and 
p110β, which was only present in 5% of the tumors (data not shown). Additionally, the 
expression of the anti-apoptotic protein Bcl-2 was assessed in SCLC patient samples. The IHC 
staining of a TMA with a specific antibody revealed a high Bcl-2 over-expression in ~90% (35/39 
cases) of the SCLC patient samples (Fig. 1C+D), compared to normal lung tissue, which did not 
display detectable levels of Bcl-2. 
 
Class IA PI3K p110α inhibition or silencing blocks cell proliferation and Akt/mTOR 
signaling 
Previous work had shown that targeting the PI3K/Akt/mTOR pathway by using small molecule 
inhibitors impaired SCLC proliferation in vitro and in vivo. Therefore, we investigated the impact 
of isoform-specific inhibitors of class IA PI3K isoforms on the proliferation of SCLC cell lines. The 
potent p110α inhibitor PIK75 (IC50 in vitro = 7.8±1.7 nM) (18) significantly impaired the 
proliferation of 4 SCLC cell lines with IC50 values in the range of 50-100 nM (Fig. 2A). The p110α 
inhibitor YM024, which is much less potent against the enzyme in vitro (IC50 in vitro = 0.3 μM), 
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also impaired the proliferation of the SCLC cell line panel, but at higher concentrations (Fig. 2A). 
The potent p110β inhibitor TGX-221 (IC50 in vitro = 8.5±0.9 nM) (18) only partially impaired the 
proliferation of SCLC cell lines, but at high concentrations (Fig. 2B). In contrast, the p110δ 
inhibitor IC87114 did not significantly impair the proliferation of the cell lines under study (Fig. 
2B). We also evaluated the impact of the dual p110α/mTOR inhibitor PI103 in the panel of SCLC 
cell lines. PI103 displayed anti-proliferative activity against the SCLC panel in vitro, with IC50 
values in the range of 100-500 nM (Suppl. Fig. 1A).  
 The impact of the selective PI3K inhibitors on the activation status of the Akt/mTOR 
pathway in SCLC cell lines was then investigated by Western blot analysis (Fig. 2C). PIK75 and 
PI103 strongly affected the activation status of Akt and the phosphorylation of the mTOR 
downstream targets ribosomal S6 protein and 4E-BP1 (Fig. 2C; Suppl. Fig. 1B). YM024 also 
impaired Akt activation and partially inhibited mTOR pathway activation (Fig. 2C; Suppl. Fig. 1B). 
In contrast, TGX221 was less effective at blocking the activation of the Akt/mTOR pathway (Fig. 
2C; Suppl. Fig. 1B).  
 To validate our findings with pharmacological inhibitors, we used RNA interference to 
down-regulate the expression of p110α or p110β in SCLC cell lines. Transient down-regulation 
of p110α strongly impaired the activation of Akt and phosphorylation of the ribosomal S6 protein, 
while p110β silencing was ineffective (Fig. 3A). In addition, p110α silencing induced a significant 
decrease in the proliferation of SCLC cells (40% reduction), while p110β down-regulation was 
less effective (25% reduction) (Fig. 3B).  We also used lentiviral delivery of short hairpin RNAs 
targeting p110α in SCLC cell lines. Also this approach resulted in stable silencing of p110α, 
robust affected PI3K downstream signaling (Fig. 3C) and SCLC cell proliferation was partially 
impaired by shRNA targeting of p110α (Fig. 3D). 
Together these results show that targeting p110α selectively impairs cell proliferation and 
activation of the Akt/mTOR pathway in SCLC cell lines in vitro.  
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Class IA PI3K p110α inhibition induces apoptosis and autophagy in SCLC cell lines 
Previous work had shown that targeting the PI3K/Akt/mTOR pathway by using small molecule 
inhibitors (7, 19) induced apoptosis in SCLC cell lines. Therefore, we investigated the impact of 
isoform-specific inhibitors of class IA PI3K isoforms on the survival of SCLC cell lines. Treatment 
of a panel of SCLC cell lines with PIK75 or YM024 induced cleavage of PARP and reduction of 
pro-caspase3, which are markers of apoptosis induction (Fig. 4A), whereas TGX221 was less 
efficient at inducing apoptosis (Fig. 4A). The induction of apoptosis upon p110α inhibition 
appeared to be stronger in the SCLC cell lines H69 and H209, compared to the effects observed 
in H510 (intermediate) and SW2 (low) (Fig. 4A). The caspase inhibitor zVAD-FMK was able to 
rescue 20% of the PIK75-induced apoptosis in H69 cells and 10% of the TGX221-induced 
apoptosis (p<0.01) (Fig. 4B). Because the strongly affected cell viability in SCLC cells upon 
p110α inhibition could not only be explained by the apoptotic cell response, we further 
investigated other cell death mechanisms, such as autophagy. Whereas the inhibition of p110α 
with PIK75 or YM024 induced an increased conversion of LC3-I to LC3-II, which is indicative for 
autophagic activity, a comparable response could not be observed in cells where p110β was 
inhibited (Fig. 4C, Suppl. Fig. 2). ATG5, another protein used as a typical marker for autophagy, 
was also expressed in SCLC cells. Compared to the vehicle-treated control, enhanced ATG5 
expression was not, or only slightly, observed in PIK75-treated H69 cells (Fig. 4C). Interestingly, 
at later time points, a decrease in ATG5 expression was observed (data not shown). 
Chloroquine is known to inhibit autophagic activity due to de-acidification of lysosomes, followed 
by accumulation of ineffective autophagic vesicles. In H69 cells treated with the PI3K inhibitors 
PIK75 and TGX221, chloroquine was able to rescue 20% (and 10% respectively) of the 
autophagy-induced decrease in cell viability (Fig. 4D), suggesting additive roles, or crosstalk, 
between autophagy and apoptosis in p110α-induced cell death.  
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Inhibition of the PI3K p110α impairs SCLC tumor formation and vascularization in vivo 
Together the data collected from our experiments and the known literature indicated an 
important role for p110α in SCLC cell growth and survival processes in vitro and in vivo. To 
further investigate its impact on tumor formation and maintenance, an in vivo assay was 
employed to grow vehicle- and PIK75-treated H69 cells on the chorioallantoic membrane (CAM) 
of chick embryos. Tumor formation was clearly impaired upon PIK75 treatment, which was 
shown by strongly reduced tumor size and tumor weight compared to the control treatment (Fig. 
5A). Additionally, IHC staining of PIK75-treated tumor sections showed a decreasing expression 
of the proliferation marker Ki67 and a rising expression of the apoptotic marker cleaved 
caspase-3 with increasing PIK75 concentrations (Fig. 5C). Finally, p110α inhibition was able to 
partially prevent the vascularization on the CAM around the tumorigenic area, as measured by 
the vessel density (Fig. 5B). Another indication of impaired tumor vascularization upon p110α 
inhibition is the reduced VEGFA expression observed in the DNA microarray and quantitative 
RT-PCR analysis of PIK75-treated H69 cells (data not shown).  
 
DNA microarray analysis of SCLC cells treated with isoform-specific PI3K inhibitors 
In order to investigate whether the class IA PI3K isoform p110α controls the expression of 
specific gene subsets in SCLC, we performed DNA microarray analysis in H69 cells treated with 
either vehicle, PIK75 targeting p110α, or TGX221 targeting p110β (Fig. 6A). The efficacy of the 
down-regulation of the Akt/mTOR pathway by the respective inhibitors was demonstrated by 
Western blot analysis, as well as quantitative RT-PCR for VEGFA expression (Fig. 2C and data 
not shown). Inhibiting p110α significantly affected the expression of 3411 genes (P-value 0.01; 
FC ≥ 1.5), while inhibiting p110β resulted in significant changes (P-value 0.01; FC ≥ 1.5) in 4 
genes, suggesting an important role of p110α, but not p110β, for the regulation of the expression 
of a subset of genes in SCLC (Fig. 6A). We next sought to investigate which genes were 
selectively affected by p110α inhibition, in comparison to p110β. Amongst these genes, anti-
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apoptotic proteins of the Bcl-2 family of proteins were found to be more significantly down-
regulated in SCLC cells treated with p110α inhibitor, than in the case of the p110β inhibitor 
(Table 1).  
 
The proteins of the Bcl-2 family are downstream targets of p110α 
In order to validate the Bcl-2 family proteins as targets of p110α in SCLC cell lines, we used 
antibody arrays and Western blot analysis to confirm the results obtained by DNA microarrays. 
An analysis using antibody arrays revealed impaired Akt pathway activation and down-regulation 
of anti-apoptotic Bcl-2 family proteins (data not shown). Down-regulation of the expression and 
impaired activation of the anti-apoptotic Bcl-2 family proteins could indeed be demonstrated at 
the protein level upon p110α inhibition (Fig. 6B). As was already observed previously for the 
apoptotic response, the SCLC cell lines under study responded varyingly to p110α inhibition. In 
particular, the cell lines H69 and H209 displayed a strongly decreased expression of the Bcl-2 
family members Bcl-2, Bcl-XL and Mcl-1, whereas SW2 cells appeared to be more resistant. In 
addition, p110α inhibition induced the levels of the pro-apoptotic family members Bad and Bax 
(Fig. 6B). In contrast to the inhibitors of p110α, TGX221 had little effect on the expression levels 
of Bcl-2 family proteins (Fig. 6B). The anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-XL are 
known targets of the NF-κB transcriptional network, which controls different cell responses 
including immune response, cell proliferation and survival (20). To gain insight into the 
transcriptional networks affected by silencing of p110α in SCLC cells, we performed a 
biostatistical analysis of the gene expression data, using GeneGo. The transcriptional networks 
that were most significantly altered comprised HNF4α, SP1 and c-Myc, the estrogen receptor 
(ER) and also NF-κB (Suppl. Table 1). We could indeed observe a deregulation of NF-κB 
expression in H69 cells treated with PIK75 and YM024, whereas p110β inhibition did not have 
any effect (Fig. 6C).These results suggested NF-κB to be a downstream target of PI3K p110α 
signaling in SCLC and, therefore, we assumed that targeting NF-κB may have an effect on the 
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expression of Bcl-2 and Bcl-XL. This hypothesis was confirmed by the observation that the 
expression levels of Bcl-2 were indeed decreased in H69 cells treated with wedelolactone, an 
inhibitor of the IκB-kinase (IKK) (Fig. 6D).  
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Discussion 
 
The PI3K/Akt/mTOR pathway has been demonstrated to play a key role in SCLC cell 
proliferation, survival, chemoresistance and migration. Mutations in PIK3CA and gene 
amplification were reported in primary SCLC, as well as increased expression of PIK3CA at the 
mRNA and protein level. Broad specificity PI3K/mTOR inhibitors have shown anti-tumor activity 
in SCLC models in vitro and in vivo (21). In this report, we have investigated the impact of 
isoform-specific inhibitors and RNAi targeting class IA PI3K isoforms on SCLC cell responses. In 
general, agents targeting p110α reduced SCLC cell proliferation in vitro, impaired the SCLC 
tumor formation, which was accompanied by affected vascularization in vivo, and decreased the 
activation status of classical PI3K downstream targets, such as Akt, mTOR and S6K. Targeting 
p110α by RNAi or isoform-specific inhibitors had more pronounced effects on SCLC cell 
responses than in the case of p110β or p110δ, indicating a selective role for p110α in SCLC. In 
view of these observations, we hypothesized that p110α may control the expression of a 
selective subset of genes implicated in SCLC cell proliferation and/or survival. The comparative 
DNA microarray analysis of SCLC cell lines in which either p110α or p110β were inhibited by 
selective compounds identified such a gene subset. The Bcl-2 family of proteins was validated 
as a downstream target of p110α by a combination of approaches. The observation that Bcl-2 
expression was elevated in primary SCLC, in comparison to normal lung tissue further supports 
this model, in view of the over-expression of p110α. Importantly, the Bcl-2 family of proteins has 
been previously shown to play a crucial role in the survival of SCLC cell lines in vitro and in vivo 
(5, 22-26). The p110α inhibitors induced increases in both SCLC apoptosis and autophagy, 
which is consistent with Bcl-2 family proteins being a target of p110α. Bcl-2 family proteins are 
key regulators of both apoptosis and autophagy (27) and their reduced expression upon 
inhibition of the p110α/NFκB pathway may play an essential role in the effects of the 
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p110α inhibitors in SCLC.  
 We have previously evaluated the mTOR inhibitor everolimus in SCLC cell lines and 
found that it was effective in a subset of SCLC cell lines characterized by activation of the 
Akt/mTOR pathway and low expression levels of anti-apoptotic Bcl-2 family proteins (24). In view 
of the results obtained with isoform-selective inhibitors of p110α, it can be speculated that these 
agents may be more potent, since they induce a down-regulation of anti-apoptotic Bcl-2 family 
proteins and of the activity of the Akt/mTOR pathway. This may be particularly relevant for SCLC 
tumors bearing activating mutations in the PIK3CA gene. 
 Interestingly, our previous work in neuroblastoma has shown that the class IA PI3K 
isoform p110δ contributes to cell proliferation and survival by controlling the activation of the 
mTOR pathway and the expression levels of anti-apoptotic Bcl-2 family proteins. Over-
expression of p110δ was found in a subset of primary neuroblastoma and cell lines, and p110δ 
was essential for signal transduction by receptor tyrosine kinases, such as the IGF-1R and 
EGFR (28). In contrast, in SCLC cell lines, p110α appears to play a more important role in the 
activation of the Akt/mTOR pathway, which may explain the impact of agents targeting this 
isoform on SCLC proliferation and survival. A previous report has shown that the activity of any 
class IA PI3K isoform can maintain cell survival (29). Therefore, the relative importance of class 
IA PI3K isoforms in selected cancer types may be, in part, attributed to differences in expression 
levels. 
 Thus, targeting PI3K p110α signaling may represent an attractive novel approach to 
develop novel therapies for SCLC. Indeed, different pharmacological inhibitors of this isoform 
now exist, which will soon enter clinical trials in oncology, and could, in the future, be developed 
as new drugs for SCLC.  
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Figure legends 
 
Fig. 1 Expression of the PI3K p110α and p110β, and the anti-apoptotic protein Bcl-2 in 
SCLC patient samples. (a) Immunostaining with PI3K p110α and p110β showing negative 
SCLC staining and representative p110α and p110β SCLC positive staining, compared to 
normal lung tissue. (b) Analysis of the IHC staining PI3K p110α and p110β in SCLC patient 
samples.(c) Immunostaining with Bcl-2 showing negative and representative Bcl-2 intermediate 
and strongly positive SCLC staining. (b) The mean immunohistochemical staining scores (IHC 
scores) Bcl-2 in 20 paraffin-embedded specimens each of normal lung tissue and of 40 SCLC 
paraffin-embedded specimens. IHC scores = percentage of positive cells x staining intensity (for 
details see “Material and Methods”).  
 
Fig. 2 PI3K inhibition blocks cell viability and PI3K downstream signaling. (a+b) The SCLC 
cell lines H69, H209, H510, and SW2 were incubated with increasing concentrations of the class 
I PI3K inhibitors PIK75, YM024 (a), TGX221, and IC87114 (b) in serum-containing medium. Cell 
viability was assessed using the MTS assay after 3 days. The data are mean with SD from four 
replicates and at least three independent experiments. (c) H69 cells were incubated with 
increasing concentrations of the PI3K p110α inhibitors PIK75, YM024, and PI103 (PI3K 
p110α/mTOR inhibitor) and the PI3K p110β inhibitor TGX221. After 24 h, the cells were 
harvested and whole cell lysates analyzed by SDS-PAGE and Western blotting for the proteins 
indicated.  
 
Fig. 3 Silencing of p110α but not p110β affects cell viability and PI3K downstream 
signaling activation. (a+c) H69 cells were transiently transfected with siRNA constructs 
targeting p110α or p110β, or non-targeting scrambled control (a) or p110α was stably silenced 
by the lentiviral delivery of shRNA constructs (c). Cell lysates were analyzed by SDS-PAGE and 
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Western blotting with antibodies for the proteins indicated. (b+d) Cell viability of H69 cells 
transiently (b) or stably (d) transfected with constructs targeting p110α or p110β was assessed 
using the MTS assay after 2 and 3 days. A non-targeting construct was used as control. 
 
Fig. 4 PI3K inhibition increases apoptosis and autophagy in SCLC. (a+c) H69, H209, H510 
and SW2 cells grown in serum-containing medium were incubated with increasing 
concentrations of the PI3K p110α inhibitors PIK75 and YM024, the PI3K p110β inhibitor 
TGX221, PI103 (PI3K p110α/mTOR inhibitor), RAD001 or etoposide/cisplatin. After 24 hours the 
cells were harvested and cell lysates analyzed by SDS-PAGE and Western blotting for the 
proteins indicated. (b+d) H69 cells grown in serum-containing medium were incubated with the 
PI3K inhibitors PIK75 (0.05 µM) and TGX221 (10 µM), rapamycin (0.1 μg/ml) or etoposide (10 
µM) in absence or presence of zVAD-FMK (50 µM) or chloroquine (20 µM). Cell proliferation was 
assessed using the MTS assay after 12h. The data are mean of four replicates and three 
independently performed experiments. ** p<0.01, * p<0.05. 
 
Fig. 5 PI3K inhibition reduces tumor formation and vascularization in vivo. (a) H69 cells 
were treated with vehicle or different concentrations of PIK75 and applied on the CAM of chick 
embryos. On day 13, pictures and tumors were taken to analyze tumor size, weight (a) and 
vessel density (b). (b) Analysis of the vessel density reduction upon PI3K p110α inhibition in 
vehicle- or PIK75-treated H69 tumors (c) Immunostaining with Ki67 and cleaved caspase-3 
comparing the expression in vehicle- and PIK75-treated SCLC tumor sections. (d) Analysis of 
Ki67 or caspase-3 positively stained tumor cells comparing vehicle- and PIK75-treated H69 
tumor sections. Positively stained cells [%] = number of positive cells/total number of cells x 100. 
*** p<0.001, ** p<0.01, * p<0.05. 
 
 
Research. 
on March 14, 2014. © 2012 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 21, 2012; DOI: 10.1158/1078-0432.CCR-12-1138 
23 
 
Fig. 6 The proteins of the Bcl-2 family are downstream targets of p110α. (a) Gene 
expression analysis by DNA microarray: Heatmap of gene expression changes caused by 
p110α inhibition. (b+c+d) H69, H209 and SW2 (b) or H69 (c+d) cells grown in serum-containing 
medium were incubated with increasing concentrations of the PI3K p110α inhibitors PIK75 and 
YM024, the PI3K p110β inhibitor TGX221, RAD001 and etoposide/cisplatin or the IKK inhibitor 
wedelolactone (d). After 24 h, the cells were harvested and cell lysates analyzed by SDS-PAGE 
and Western blotting for the proteins indicated. 
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